Soleno Therapeutics, Inc. (SLNO)
May 18, 2026 - SLNO was delisted (reason: acquired by NBIX)
53.01
0.00 (0.00%)
Inactive · Last trade price on May 15, 2026
Soleno Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 133.03 | 70.11 | 87.93 | 169.68 | 14.6 | 21.3 |
Short-Term Investments | 122.57 | 235.37 | 203.51 | - | - | - |
Cash & Short-Term Investments | 255.6 | 305.47 | 291.44 | 169.68 | 14.6 | 21.3 |
Cash Growth | -11.85% | 4.82% | 71.76% | 1062.04% | -31.46% | -56.72% |
Accounts Receivable | 47.14 | 28.21 | - | - | - | - |
Inventory | 17.31 | 15.02 | - | - | - | - |
Other Current Assets | 6.33 | 7.11 | 2.45 | 1.68 | 1.05 | 1.12 |
Total Current Assets | 326.38 | 355.81 | 293.89 | 171.36 | 15.65 | 22.42 |
Net Property, Plant & Equipment | 4.09 | 2.38 | 2.98 | 0.42 | 0.16 | 0.45 |
Other Intangible Assets | 4.37 | 4.86 | 6.81 | 8.75 | 10.69 | 12.64 |
Long-Term Investments | 273.38 | 200.62 | 27.21 | - | - | - |
Other Long-Term Assets | 0.16 | 0.16 | 0.08 | 0.17 | - | 0.04 |
Total Assets | 608.39 | 563.83 | 330.97 | 180.69 | 26.5 | 35.55 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 12.39 | 12.44 | 8.88 | 3.15 | 1.78 | 3.25 |
Accrued Expenses | 5.72 | 9.68 | 4.78 | 6.53 | 4.9 | 4.15 |
Current Portion of Leases | 1.16 | 0.73 | 0.53 | 0.27 | 0.16 | 0.28 |
Other Current Liabilities | 38.78 | 38.53 | 4.56 | 1.56 | 0.48 | 0.32 |
Total Current Liabilities | 58.05 | 61.36 | 18.75 | 11.51 | 7.31 | 8.01 |
Long-Term Debt | 49.87 | 49.86 | 49.83 | - | - | - |
Long-Term Leases | 3.24 | 1.96 | 2.47 | 0.13 | - | 0.18 |
Other Long-Term Liabilities | 1.43 | 0.53 | 14.81 | 11.55 | 8.84 | 9.58 |
Total Long-Term Liabilities | 54.54 | 52.35 | 67.11 | 11.68 | 8.84 | 9.75 |
Total Liabilities | 112.59 | 113.72 | 85.86 | 23.18 | 16.15 | 17.76 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.05 | 0.05 | 0.05 | 0.03 | 0.01 | 0.08 |
Additional Paid-in Capital | 897.58 | 881.02 | 696.97 | 433.89 | 247.76 | 231.07 |
Accumulated Other Comprehensive Income | -1.84 | 0.42 | 0.36 | - | - | - |
Retained Earnings | -399.99 | -431.37 | -452.26 | -276.41 | -237.42 | -213.36 |
Shareholders' Equity | 495.8 | 450.12 | 245.11 | 157.51 | 10.35 | 17.79 |
Total Liabilities & Equity | 608.39 | 563.83 | 330.97 | 180.69 | 26.5 | 35.55 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 54.28 | 52.55 | 52.83 | 0.4 | 0.16 | 0.46 |
Net Cash (Debt) | 201.32 | 252.92 | 238.61 | 169.28 | 14.45 | 20.85 |
Net Cash Growth | -15.11% | 6.00% | 40.96% | 1071.72% | -30.70% | -57.53% |
Net Cash Per Share | 3.78 | 4.83 | 5.94 | 10.26 | 1.72 | 3.92 |
Book Value | 495.8 | 450.12 | 245.11 | 157.51 | 10.35 | 17.79 |
Book Value Per Share | 9.32 | 8.59 | 6.10 | 9.55 | 1.23 | 3.35 |
Tangible Book Value | 491.43 | 445.25 | 238.31 | 148.76 | -0.35 | 5.16 |
Tangible Book Value Per Share | 9.24 | 8.50 | 5.93 | 9.02 | -0.04 | 0.97 |